Glycanostics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
20
- Latest Deal Type
-
Later Stage VC
- (Upcoming)
- Latest Deal Amount
-
$5.8M
- Investors
-
6
Glycanostics General Information
Description
Developer of cancer diagnostics equipment designed to provide accurate, affordable and non-invasive tests for cancer. The company's diagnostics technology includes prostate cancer kit products for use analysis of glycan changes on specific proteins, like a prostate-specific antigen (PSA), enabling doctors to make a proper decision about the need to perform a biopsy or to check the patient after the biopsy.
Contact Information
Website
www.glycanostics.comCorporate Office
- Kudlákova 7
- Bratislava, 841 01
- Slovakia
Corporate Office
- Kudlákova 7
- Bratislava, 841 01
- Slovakia
Glycanostics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC | $5.8M | Upcoming | Generating Revenue | |||
| 6. Accelerator/Incubator | 01-Jan-2023 | Completed | Generating Revenue | |||
| 5. Equity Crowdfunding | 01-Jun-2022 | Completed | Generating Revenue | |||
| 4. Grant | 01-Oct-2021 | Completed | Generating Revenue | |||
| 3. Seed Round | 07-Oct-2020 | Completed | Generating Revenue | |||
| 2. Grant | 10-Oct-2019 | $110K | Completed | Generating Revenue | ||
| 1. Grant | 10-Dec-2018 | $56.8K | Completed | Generating Revenue |
Glycanostics Patents
Glycanostics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026195647-A1 | Calibration curve generated using known amounts of wfl-detectable fpsa obtained from lncap cells | Pending | 17-Mar-2025 | ||
| AU-2023251663-A1 | Means and methods for high-throughput glycoprofiling of proteins | Pending | 12-Apr-2022 | ||
| EP-4508429-A1 | Means and methods for high-throughput glycoprofiling of proteins | Pending | 12-Apr-2022 | ||
| US-20250258166-A1 | Means and methods for high-throughput glycoprofiling of proteins | Pending | 12-Apr-2022 | ||
| WO-2023198337-A1 | Means and methods for high-throughput glycoprofiling of proteins | Inactive | 12-Apr-2022 | G01N33/54313 |
Glycanostics Signals
Glycanostics Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Medical Forge | Accelerator/Incubator | |||
| European Innovation Council | Accelerator/Incubator | Minority | ||
| CB Investment Management | Growth/Expansion | Minority | ||
| Slovak Investment Holding | Growth/Expansion | Minority | ||
| Nadaciaeset | Government |
Glycanostics FAQs
-
When was Glycanostics founded?
Glycanostics was founded in 2017.
-
Where is Glycanostics headquartered?
Glycanostics is headquartered in Bratislava, Slovakia.
-
What is the size of Glycanostics?
Glycanostics has 20 total employees.
-
What industry is Glycanostics in?
Glycanostics’s primary industry is Diagnostic Equipment.
-
Is Glycanostics a private or public company?
Glycanostics is a Private company.
-
What is Glycanostics’s current revenue?
The current revenue for Glycanostics is .
-
How much funding has Glycanostics raised over time?
Glycanostics has raised $2.18M.
-
Who are Glycanostics’s investors?
Medical Forge, European Innovation Council, CB Investment Management, Slovak Investment Holding, and Nadaciaeset are 5 of 6 investors who have invested in Glycanostics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process